Dilated cardiomyopathy has led to an increase in heart failures worldwide among adults and children also giving rise to need for heart transplant. Dilated cardiomyopathy can develop between the ages of 20 and 40 years, genetic inheritance being the most common factor affecting 30%-40% of the DCM patients globally. Due to the increasing cases of heart failures, the demand for dilated cardiomyopathy drugs is expected to increase as the need for blockbuster drugs in developed countries is becoming evident.
According to a report published by Transparency Market Research, the global dilated cardiomyopathy therapeutics market is expected to witness a negative CAGR of -7% from 2014 to 2020. The global dilated cardiomyopathy market was valued at US$651 mn in 2013 and is projected to decrease to US$328.6 mn by 2020.
How can an increase in heart failure cases help drug manufacturers to develop innovative and advanced therapeutics?
According to a study, in every one million children across the globe, six are diagnosed with dilated cardiomyopathy. It is found commonly among children who are under the age of 2 years. There has also been a substantial increase in the number of heart failures among adults as well, leading to a global rise in the demand for dilated cardiomyopathy therapeutics. Of the overall congestive heart failures that occur each year, DCM comprises 30%-40%. Due to this, several leading companies have introduced clinical trials and invested for the development of therapeutics for dilated cardiomyopathy.
For instance, Cincinnati Children’s Heart Institute announced a breakthrough development on 19 May, 2016 where genetically inherited heart diseases can be diagnosed and treated with the help of biomechanics and stem cells. Similar breakthroughs are underway in the field of dilated cardiomyopathy drugs to help in the growth of the market with better techniques and medications.
What factors are responsible for the negative growth of the dilated cardiomyopathy therapeutics market?
DCM drugs segment has no drug that has been approved by FDA till date. The drugs used for the treatment of dilated cardiomyopathy and congestive heart failure are same and have no distinct formulation. DCM drugs are reported to have side effects and this has thus affected revenues from DCM therapeutics substantially. The use of devices and gene therapy that provide enhanced relief without any side effect has highly restrained the dilated cardiomyopathy therapeutics market growth globally.
Interpret a Competitive outlook Analysis Report with free PDF Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
However, companies in the DCM drug market along with research organizations are working on the approval of aldosterone antagonists combined with ARBs or ACE. It is expected that these drugs will play a positive role in reducing the progress of Duchenne muscular dystrophy. This approval will help in the acceleration of sales of DCM drugs as aldosterone antagonists are one of the main additives in the formulation of DCM medications.
The increase in genericization activities of DCM drugs will also provide manufacturers with opportunities to improve their product position in the global market and also witness a positive growth of the DCM drugs market.
North America dominated the DCM drugs market in 2013 due to the demand for branded drugs and increasing heart failure cases. Asia Pacific is projected to be the fastest growing market for DCM followed by the Rest of the World owing to the per capita income increase, and improving economic standards in the region. Some of the key players operating in the global DCM drugs market are Celladon Corporation, Novartis International AG, Vericel Corporation, Sanofi S.A., AstraZeneca plc, and GlaxoSmithKilne plc.